PARAGARD has high patient satisfaction

*Data are from the Contraceptive CHOICE Project. The study evaluated 3- and 6-month self-reported bleeding and cramping patterns in 5011 Long-Acting Reversible Contraceptive (LARC) users (n=826, PARAGARD), and the association of these symptoms with method satisfaction. Study participants rated satisfaction with their LARC method as "very satisfied," "somewhat satisfied," or "not satisfied." For the data analyses, "satisfied" and "very satisfied" were grouped together as "satisfied."1

Bleeding Profile

PARAGARD users may experience heavier, longer periods and spotting between periods after placement, but this generally subsides after 2-3 months2

PARAGARD is hormone free, so patients should keep their menstrual cycle3
  • Some women may wish to keep a menstrual cycle for a variety of personal or cultural reasons4

Patients should be advised to call their healthcare professional if spotting persists or their menstrual flow continues to be heavy or long if a woman misses her period, she must promptly be evaluated for pregnancy2

Continuation Rates

Contraceptive continuation rates at 12 months among women ≥26 years of age (n=2956)5†‡

LNG-20-US=Ievonorgestrel 20 mcg/day intrauterine system.
From the Contraceptive CHOICE Project (n=7472). A prospective cohort study to determine the continuation rates and satisfaction levels with many reversible methods of contraception. To be included in this analysis, study participants had to initiate their chosen contraceptive within 3 months of CHOICE enrollment and reach the time point for a 12-month follow-up telephone survey. Follow-up telephone interviews were conducted at 3, 6, and 12 months. A "continuer" was a participant who reported using her baseline contraceptive without stopping temporarily for ≥1 month.5
Chart does not compare the safety or efficacy of these methods.

Reference: 1. Diedrich JT, Desai S, Zhao Q, et al. Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction. Am J Obstet Gynecol. 2015;212(1): 50.e1-50.e8. 2. PARAGARD® T 380A [Prescribing Information]. Trumbull, CT. CooperSurgical, Inc. 3. Kaneshiro B, Aeby T. Long-term safety, efficacy, and patient acceptability of the intrauterine Copper T-380A contraceptive device. lnt J Womens Health. 2010;2:211-220. 4. Data on file. Market research, June 2015. CooperSurgical, Inc. 5. Rosenstock JR, Peipert JF, Madden T, et al. Continuation of reversible contraception in teenagers and young women. Obstet Gynecol. 2012;120(6):1298-1305.